1984 Volume 32 Issue Supplement4 Pages 252-259
Clinical study was made on sulbactam/cefoperazone, a new β-lactamase inhibitor combined with a new cephem.
The results were as follows.
1) Sulbactam/Cefoperazone was found effective in 50% of 22 patients with respiratory tract infection.
2) Sulbactam/Cefoperazone was found effective in 44.4% of 18 patients with lower airway infection.
3) Sulbactam/Cefoperazone was found effective in 75% of 4 patients with pneumonia.
4) H. influenzae, which were isolated in each sputum of seven patients, were totally eradicated with thisdrug, but for six patients with P. aeruginosa infection, this drug was not effective.
5) Sulbactam/Cefoperazone caused eosinophilia in one case and leukopenia in one case but these findingswere alleviated rapidly following cessation of the drug. In another one case, this drug caused antabuselike effect after his taking alcohol. But this symptom disappeared completely in about three hourswithout any medical treatment.
